CY1115310T1 - Χρηση ολιγομερων γαλακτικου οξεος στη αντιμετωπιση γυναικολογικων λοιμωξεων - Google Patents

Χρηση ολιγομερων γαλακτικου οξεος στη αντιμετωπιση γυναικολογικων λοιμωξεων

Info

Publication number
CY1115310T1
CY1115310T1 CY20141100463T CY141100463T CY1115310T1 CY 1115310 T1 CY1115310 T1 CY 1115310T1 CY 20141100463 T CY20141100463 T CY 20141100463T CY 141100463 T CY141100463 T CY 141100463T CY 1115310 T1 CY1115310 T1 CY 1115310T1
Authority
CY
Cyprus
Prior art keywords
lactic acid
infection
treatment
vaginitis
bacterial
Prior art date
Application number
CY20141100463T
Other languages
Greek (el)
English (en)
Inventor
Greg Batcheller
Thomas Hedner
Jörgen Johnson
Werner Schubert
Christer Sjögren
Olov Sterner
Malgorzat Sznitowska
Original Assignee
Laccure Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laccure Ab filed Critical Laccure Ab
Publication of CY1115310T1 publication Critical patent/CY1115310T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20141100463T 2007-03-30 2014-06-26 Χρηση ολιγομερων γαλακτικου οξεος στη αντιμετωπιση γυναικολογικων λοιμωξεων CY1115310T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700508 2007-03-30
EP08734874.4A EP2142186B1 (en) 2007-03-30 2008-03-28 Use of oligomers of lactic acid in the treatment of gynaecological infections

Publications (1)

Publication Number Publication Date
CY1115310T1 true CY1115310T1 (el) 2017-01-04

Family

ID=39494560

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100463T CY1115310T1 (el) 2007-03-30 2014-06-26 Χρηση ολιγομερων γαλακτικου οξεος στη αντιμετωπιση γυναικολογικων λοιμωξεων

Country Status (19)

Country Link
US (3) US8425894B2 (enExample)
EP (2) EP2679222A1 (enExample)
JP (2) JP5409596B2 (enExample)
KR (1) KR101518014B1 (enExample)
CN (2) CN103830216B (enExample)
AU (1) AU2008234064B2 (enExample)
BR (1) BRPI0809330B8 (enExample)
CA (1) CA2681803C (enExample)
CY (1) CY1115310T1 (enExample)
DK (1) DK2142186T3 (enExample)
ES (1) ES2482190T3 (enExample)
HR (1) HRP20140559T1 (enExample)
MX (1) MX2009010445A (enExample)
PL (1) PL2142186T3 (enExample)
PT (1) PT2142186E (enExample)
RU (1) RU2459620C2 (enExample)
SI (1) SI2142186T1 (enExample)
WO (1) WO2008119518A1 (enExample)
ZA (1) ZA200907215B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2459620C2 (ru) 2007-03-30 2012-08-27 Лаккуре Аб Применение олигомеров молочной кислоты в лечении гинекологических расстройств
CN101797269B (zh) * 2010-03-23 2012-01-04 杨霞 一种调节女性阴道微生态的生理平衡液
RU2422147C1 (ru) * 2010-03-29 2011-06-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ лечения неспецифического аэробного вагинита
WO2012158779A1 (en) 2011-05-17 2012-11-22 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
CN102274333A (zh) * 2011-08-22 2011-12-14 谢英华 一种治疗阴道炎的外洗中药
CN102579829B (zh) * 2012-03-06 2013-09-18 康莉 一种治疗牛放线菌病的中药组合物及其制备方法
WO2013187984A1 (en) 2012-06-13 2013-12-19 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
BR112015001006B1 (pt) * 2012-07-16 2022-05-17 Laccure Ab Composição que compreende ácido lático oligomérico, e método para a preparação da composição
CN102885850B (zh) * 2012-10-15 2013-08-07 山东省医疗器械研究所 一种治疗阴道炎的多孔凝胶颗粒剂
NZ722215A (en) 2013-12-19 2019-02-22 Evofem Inc Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
US9895311B2 (en) * 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
DK3439633T3 (da) 2016-04-06 2021-12-20 Gedea Biotech Ab Glucono delta-lacton til behandling af vaginale svampeinfektioner
US10249017B2 (en) * 2016-08-11 2019-04-02 Intel Corporation Apparatus and method for shared resource partitioning through credit management
US20190209502A1 (en) * 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
AU2017338748A1 (en) 2016-10-04 2019-05-02 Evofem Inc. Method of treatment and prevention of bacterial vaginosis
JP7219712B2 (ja) * 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 膣送達のための凍結乾燥医薬組成物
LT3773501T (lt) * 2018-03-29 2024-01-10 The Materia Company Limited Intravaginalinis preparatas
US20220096349A1 (en) * 2019-02-13 2022-03-31 Miyoshi Oil & Fat Co., Ltd. Cosmetic compounding agent, cosmetic and production method thereof
WO2023165971A1 (en) 2022-03-01 2023-09-07 Laccure Ab Process for preparation of compositions of oligomers of lactic acid
EP4590289A4 (en) * 2023-07-07 2025-11-26 Changchun Sinobiomaterials Co Ltd MUSCLE ATROPHY

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431427A (en) * 1981-10-05 1984-02-14 University Of Delaware Tampons and their manufacture
US5274127A (en) * 1990-09-18 1993-12-28 Biopak Technology, Ltd. Lactide production from dehydration of aqueous lactic acid feed
JP2919912B2 (ja) 1990-05-23 1999-07-19 鐘紡株式会社 修飾プロテアーゼ及びその製造法
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
JPH07132127A (ja) 1993-06-17 1995-05-23 Mitsui Toatsu Chem Inc 生理用ナプキン
DE19506395A1 (de) 1994-02-24 1995-08-31 Ecological Chem Prod Zusammensetzung und Verfahren zum Verpacken feuchtigkeitshaltiger Lebensmittel
US5521278A (en) * 1994-08-18 1996-05-28 Ecological Chemical Products Integrated process for the manufacture of lactide
JP2864218B2 (ja) 1994-12-06 1999-03-03 株式会社日本製鋼所 ポリ乳酸共重合体の製造方法
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
JPH09227388A (ja) * 1996-02-15 1997-09-02 Naganushi Tetsuaki 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤
AU2459497A (en) 1996-05-31 1998-01-05 Research And Development Institute, Inc. Urinary medical devices
US6229046B1 (en) 1997-10-14 2001-05-08 Cargill, Incorported Lactic acid processing methods arrangements and products
JP2000072680A (ja) * 1998-08-25 2000-03-07 Shiyumeidou:Kk 免疫機能調節剤
JP2001139476A (ja) * 1999-11-15 2001-05-22 Youichirou Naganushi 癌を含めた悪性新生物に用いる抗悪性腫瘍剤
RU2163810C1 (ru) * 2000-05-18 2001-03-10 Майорова Нина Федоровна Состав для удаления доброкачественных новообразований на коже и слизистых и способ его получения
WO2002055090A1 (fr) * 2001-01-12 2002-07-18 Amato Pharmaceutical Products,Ltd. Agents preventifs d'infections microbiennes
EP1362594A1 (en) 2001-01-24 2003-11-19 Amato Pharmaceutical Products, Ltd. Anti-stress agents
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
JP2002275256A (ja) * 2001-03-19 2002-09-25 Tendou Seiyaku Kk 乳酸オリゴマーの製造方法
WO2003016259A2 (de) 2001-08-16 2003-02-27 Pharmacon-Forschung Und Beratung Gmbh Milchsäureelemente enthaltende verbindungen, deren herstellung sowie deren verwendung als pharmazeutische wirkstoffe
WO2003039560A1 (en) * 2001-11-06 2003-05-15 Amato Pharmaceutical Products, Ltd. Antitumor agent containing lactic acid oligomer mixture
JP2004307561A (ja) * 2003-04-02 2004-11-04 Tendou Seiyaku Kk 環状乳酸オリゴマーの製造方法
CA2523740C (en) 2003-05-01 2012-05-15 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof
JP4316299B2 (ja) * 2003-06-03 2009-08-19 学校法人東海大学 鎖状乳酸オリゴマー誘導体およびその製造方法
JP2005126361A (ja) * 2003-10-23 2005-05-19 Tendou Seiyaku Kk ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤
CN1562049A (zh) * 2004-04-02 2005-01-12 聂四平 低聚果糖在制备治疗及预防阴道炎药中的应用
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
SE528337C2 (sv) 2004-06-23 2006-10-24 Nestor Medical Ab Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet
JP2006232909A (ja) * 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸
JP4431102B2 (ja) 2005-11-11 2010-03-10 キャタピラージャパン株式会社 カウンタウエイト及びカウンタウエイトの製造方法並びに作業機械
RU2308970C1 (ru) * 2006-03-10 2007-10-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Антибактериальное средство для лечения внутриклеточных инфекций
JP2007258526A (ja) 2006-03-24 2007-10-04 Konica Minolta Holdings Inc 有機エレクトロルミネッセンス素子、及び有機エレクトロルミネッセンスディスプレイ
JP2008157576A (ja) 2006-12-26 2008-07-10 Sharp Corp 加湿機
RU2459620C2 (ru) 2007-03-30 2012-08-27 Лаккуре Аб Применение олигомеров молочной кислоты в лечении гинекологических расстройств

Also Published As

Publication number Publication date
KR101518014B1 (ko) 2015-05-06
US8425894B2 (en) 2013-04-23
MX2009010445A (es) 2010-01-29
JP2010523480A (ja) 2010-07-15
US9315444B2 (en) 2016-04-19
PL2142186T3 (pl) 2014-09-30
BRPI0809330B8 (pt) 2021-05-25
AU2008234064A1 (en) 2008-10-09
PT2142186E (pt) 2014-07-17
EP2142186B1 (en) 2014-04-30
CN103830216A (zh) 2014-06-04
HRP20140559T1 (hr) 2014-08-01
CN101677980B (zh) 2013-10-23
KR20100016060A (ko) 2010-02-12
JP5793542B2 (ja) 2015-10-14
ZA200907215B (en) 2014-03-26
EP2679222A1 (en) 2014-01-01
DK2142186T3 (da) 2014-08-04
BRPI0809330B1 (pt) 2019-12-17
RU2009140141A (ru) 2011-05-10
CN103830216B (zh) 2016-08-17
CA2681803C (en) 2014-08-05
EP2142186A1 (en) 2010-01-13
ES2482190T3 (es) 2014-08-01
JP2014012675A (ja) 2014-01-23
US20130317104A1 (en) 2013-11-28
CN101677980A (zh) 2010-03-24
WO2008119518A1 (en) 2008-10-09
US20110020265A1 (en) 2011-01-27
CA2681803A1 (en) 2008-10-09
RU2459620C2 (ru) 2012-08-27
BRPI0809330A2 (pt) 2014-09-09
AU2008234064B2 (en) 2013-02-07
JP5409596B2 (ja) 2014-02-05
US20150025142A1 (en) 2015-01-22
SI2142186T1 (sl) 2014-08-29
US8912232B2 (en) 2014-12-16

Similar Documents

Publication Publication Date Title
CY1115310T1 (el) Χρηση ολιγομερων γαλακτικου οξεος στη αντιμετωπιση γυναικολογικων λοιμωξεων
IL287381B2 (en) Pharmaceutical preparations of human rpe cells and uses thereof
WO2009129470A3 (en) Methods for treating herpes virus infections
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
FI4108671T3 (fi) Muokattuja nukleosideja, nukleotideja ja nukleiinihappoja sekä niiden käyttötapoja
CY1113949T1 (el) Αντιιικη συνθεση, η οποια περιεχει εναν θειικο πολυσακχαριτη: ι-καρραγενανη
NZ602504A (en) Antiviral vaccines with improved cellular immunogenicity
WO2001053506A3 (en) Virus strains for the oncolytic treatment of cancer
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
Hassan et al. Plumbagin, a plant‐derived compound, exhibits antifungal combinatory effect with amphotericin B against Candida albicans clinical isolates and anti‐hepatitis C virus activity
CL2008003819A1 (es) Compuestos derivados del acido 2-cetoamino benzoico sustituido, inhibidores del virus de la hepatitis c; composicion farmaceutica; y su uso en el tratamiento de una infeccion por vhc.
EA201390233A1 (ru) Фармацевтические композиции
MX385354B (es) Sales de xantilio 3,6-disustituidas.
WO2006079109A3 (en) Non-toxic antimicrobial compositions and methods using pro-oxidative polyphenols and antioxidants
IL203873A0 (en) Novel targets and compounds for therapeutic intervention of hiv infection
BRPI0606123A2 (pt) pirrolidinas fenil-substituìdas
EP2182937A4 (en) ANTIVIRAL COMPOSITION
BR112015019566A2 (pt) processo para a preparação de um copolímero
FR2792206B1 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
NI200700176A (es) Compuestos peptídicos
WO2013073998A3 (ru) Новые производные гемина с антибактериальной и противовирусной активностью
CY1113520T1 (el) Παραγωγα γλουταθειονης και χρησεις αυτων για θεραπεια ιικων νοσηματων
BRPI0411245A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv
NZ595060A (en) Treatment of cancer with immunostimulatory hiv tat derivative polypeptides